New York, NY -- (ReleaseWire) -- 04/15/2013 --Delcath Systems, Inc. (NASDAQ:DCTH) announced that as a part of the Company`s continued effort to increase efficiencies and reduce cash utilization, it has implemented a program designed to decrease the Company`s 2013 quarterly operating cash utilization to between $9 million and $10 million from the previously communicated range of $9 million to $12 million, beginning in the second half of 2013.
Combined with the Company`s approximate $42 million cash position at March 31, 2013, the program is expected to provide Delcath with sufficient resources for at least the next 12 months as the Company pursues three key objectives: U.S. FDA approval for MelblezTM Kit (Melblez (melphalan) for Injection for use with the Delcath Hepatic Delivery System), European commercialization of CHEMOSAT® Hepatic Delivery System for melphalan hydrochloride, and ongoing clinical development focused on label expansion.
Delcath Systems, Inc. is a specialty pharmaceutical and medical device company focused on oncology.
Find out more on DCTH here:
BIOLASE, Inc. (NASDAQ: BIOL) announced that it has engaged Michael Porter of Porter, LeVay & Rose, Inc. (PLR) for Investor Relations services, after deciding to replace In-Site Communications, Inc.
"We are very pleased to re-engage PLR," said Federico Pignatelli, Chairman and Chief Executive Officer. "Mr. Porter worked successfully with BIOLASE for several years in the early 2000s and has a deep understanding of the Company's technology and goals. We look forward to leveraging the breadth and depth of knowledge that Mr. Porter will bring to BIOLASE."
BIOLASE, Inc. is a biomedical company that develops, manufactures and markets dental lasers and also distributes and markets dental imaging equipment; products that are focused on technologies that advance the practice of dentistry and medicine.
Find out where BIOL could be headed here:
Stockreportdaily.com issues momentum alerts on stocks that can provide gains to day traders. Stockreportdaily.com provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more. Stockreportdaily.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals Stockreportdaily.com is often in the know of several large investor awareness campaigns being deployed.
Timing is everything when trading Penny Stocks. Gain an Edge by joining the Stockreportdaily.com newsletter and receiving alerts from a Pro-Active team of researchers. Trading Alerts believes traders should have a chance at successfully trading penny stocks and invites traders and investors to be part of the Free VIP membership.
Simply sign up for free and start receiving exclusive alerts.
Subscribe Here: http://www.Stockreportdaily.com
Stockreportdaily.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Stockreportdaily.com website, for complete risks and disclosures.
Investor Alley, its employees, officers, directors, shareholders and affiliates, hold no positions in the above-mentioned stocks.
For full disclaimer visit; http://www.Stockreportdaily.com/disclaimer/
Stock Report Daily